Testosterone Undecanoate Induces Muscle Hypertrophy in Hypogonadal U.S. Males: Morphological Insights
Reading Time: 2 minutes Introduction Testosterone deficiency, or hypogonadism, affects an estimated 4-5 million American men over 40, contributing to sarcopenia, reduced muscle mass, and diminished physical performance. Testosterone undecanoate (TU), a long-acting intramuscular depot formulation, has emerged as a cornerstone of testosterone replacement therapy (TRT). This article examines TU's impact on muscle hypertrophy—defined as an increase in myofiber cross-sectional area (CSA)—through morphological analyses, including MRI and ultrasound assessments. Drawing from recent U.S.-based cohort studies, we explore how TU restores androgenic signaling to enhance lean body mass in aging and hypogonadal American males, addressing a critical public health concern amid rising obesity and sedentary...


